סנדוסטטין 0.2 מגמל

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

OCTREOTIDE

MAH:

NOVARTIS ISRAEL LTD

ATC_code:

H01CB02

pharmaceutical_form:

תמיסה להזרקה\אינפוזיה

composition:

OCTREOTIDE 0.2 MG/ML

administration_route:

תת-עורי, תוך-ורידי

prescription_type:

מרשם נדרש

manufactured_by:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

therapeutic_group:

OCTREOTIDE

therapeutic_area:

OCTREOTIDE

therapeutic_indication:

Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients.Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

authorization_date:

2010-03-31